Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial

Cecilia Becattini, Rupert Bauersachs, Giorgio Maraziti, Laurent Bertoletti, Alexander Cohen, Jean M Connors, Dario Manfellotto, Antonio Sanchez, Benjamin Brenner, Giancarlo Agnelli, Cecilia Becattini, Rupert Bauersachs, Giorgio Maraziti, Laurent Bertoletti, Alexander Cohen, Jean M Connors, Dario Manfellotto, Antonio Sanchez, Benjamin Brenner, Giancarlo Agnelli

Abstract

The effect of renal impairment (RI) on risk of bleeding and recurrent thrombosis in cancer patients treated with direct oral anticoagulants for venous thromboembolism (VTE) is undefined. We ran a prespecified analysis of the randomized Caravaggio study to evaluate the role of RI as a risk factor for bleeding or recurrence in patients treated with dalteparin or apixaban for cancerassociated VTE. RI was graded as moderate (creatinine clearance between 30-59 mL/minute; 275 patients) and mild (between 60- 89 mL/minute; 444 patients). In the 1142 patients included in this analysis, the incidence of major bleeding was similar in patients with moderate vs. no or mild RI (HR 1.06-95% CI: 0.53-2.11), with no difference in the relative safety of apixaban and dalteparin. Recurrent VTE was not different in moderate vs. no or mild RI (HR=0.67, 95% CI: 0.38-1.20); in moderate RI, apixaban reduced recurrent VTE compared to dalteparin (HR=0.27, 95% CI: 0.08-0.96; P for interaction 0.1085). At multivariate analysis, no association was found between variation of renal function over time and major bleeding or recurrent VTE. Advanced or metastatic cancer was the only independent predictor of major bleeding (HR=2.84, 95% CI: 1.20-6.71), with no effect of treatment with apixaban or dalteparin. In our study, in cancer patients treated with apixaban or dalteparin, moderate RI was not associated with major bleeding or recurrent VTE. In patients with moderate renal failure, the safety profile of apixaban was confirmed with the potential for improved efficacy in comparison to dalteparin. ClinicalTrials.gov identifier: NCT03045406.

Keywords: Cancer-associated venous thromboembolism; Caravaggio trial.

References

    1. Prandoni P, Lensing AWA, Piccioli A, et al. . Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484-3488.
    1. Weitz JI, Haas S, Ageno W, et al. . Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. J Thromb Thrombolysis. 2020;50(2):267-277.
    1. Lee AYY, Kamphuisen PW, Meyer G, et al. . Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer. JAMA. 2015;314(7):677-686.
    1. Lee AYY, Levine MN, Baker RI, et al. . Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349(2):146-153.
    1. Raskob GE, van Es N, Verhamme P, et al. . Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615-624.
    1. Young AM, Marshall A, Thirlwall J, et al. . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017-2023.
    1. McBane RD, Wysokinski WE, Le-Rademacher J, et al. . Apixaban, dalteparin, in active cancer associated venous thromboembolism, the ADAM VTE Trial. Blood. 2018;132(Suppl 1):421.
    1. Agnelli G, Becattini C, Meyer G, et al. . Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599-1607.
    1. Key NS, Khorana AA, Kuderer NM, et al. . Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline up date. J Clin Oncol. 2020;38(5):496-520.
    1. Konstantinides SV, Meyer G, Becattini C, et al. . 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603.
    1. Lyman GH, Carrier M, Ay C, et al. . American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927-974.
    1. Goto S, Haas S, Ageno W, et al. . GARFIELD-VTE Investigators. Assessment of outcomes among patients with venousthromboembolism with and without chronic kidney disease. JAMA Netw open. 2020;3(10):e2022886.
    1. Angelini DE, Radivoyevitch T, McCrae KR, Khorana AA. Bleeding incidence and risk factors among cancer patients treated with anticoagulation. Am J Hematol. 2019;94(7):780-785.
    1. Trujillo-Santos J, Nieto JA, Tiberio G, et al. . RIETE Registry. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100(3):435-439.
    1. Bauersachs R, Lee AYY, Kamphuisen PW, et al. . CATCH Investigators. Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism-analysis of the CATCH study. Thromb Haemost. 2018;118(5):914-921.
    1. Woodruff S, Feugère G, Abreu P, Heissler J, Ruiz MT, Jen F. A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. J Thromb Thrombolysis. 2016;42(4):494-504.
    1. Bavalia R, Middeldorp S, Weisser G, Espinola-Klein C. Treatment of venous thromboembolism in special populations with direct oral anticoagulants. Thromb Haemost. 2020;120(6):899-911.
    1. van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124(12):1968-1975.
    1. Agnelli G, Becattini C, Bauersachs R, et al. . Apixaban versus Dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thromb Haemost. 2018;118(9):1668-1678.
    1. Inker LA, Astor BC, Fox CH, et al. . KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713-735.
    1. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
    1. Levey AS, Stevens LA, Schmid CH, et al. . CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.
    1. Levey AS, Coresh J, Greene T, et al. . Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247-254.
    1. Asar Ö, Ritchie J, Kalra PA, Diggle PJ. Joint modelling of repeated measurement and time-to-event data: an introductory tutorial. Int J Epidemiol. 2015;44(1):334-344.
    1. Janus N, Launay-Vacher V, Byloos E, et al. . Cancer and renal insufficiency results of the BIRMA study. Br J Cancer. 2010;103(12):1815-1821.
    1. Prins MH, Lensing AW, Brighton TA, et al. . Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014;1(01):e37-e46.
    1. Agnelli G, Buller HR, Cohen A, et al. . Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015;13(12):2187-2191.
    1. Farge D, Frere C, Connors JM, et al. . International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20(10):e566-e581.
    1. Kearon C, Akl EA, Ornelas J, et al. . Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-352.
    1. Atiq F, van den Bemt PM, Leebeek FW, van Gelder T, Versmissen J. A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency. Eur J Clin Pharmacol. 2015;71(8):921-929.
    1. Park D, Southern W, Calvo M, et al. . Treatment with dalteparin is associated with a lower risk of bleeding compared to treatment with unfractionated heparin in patients with renal insufficiency. J Gen Intern Med. 2016;31(2):182-187.
    1. Verso M, Munoz A, Bauersachs R, et al. . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. Eur J Cancer. 2021;148:371-381.
    1. Ortel TL, Neumann I, Ageno W, et al. . ASH-2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693-4738.
    1. McCormack T, Harrisingh MC, Horner D, Bewley S, Guideline Committee. Venous thromboembolism in adults: summary of updated NICE guidance on diagnosis, management, and thrombophilia testing. BMJ. 2020;369:m1565.
    1. Hohnloser SH, Hijazi Z, Thomas L, et al. . Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33(22):2821-2830.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅